Belite Bio, Inc
BLTE
$183.16
-$9.69-5.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 5.85% | 94.13% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.98% | 30.81% | |||
| Operating Income | -21.98% | -30.81% | |||
| Income Before Tax | -16.75% | -32.90% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.75% | -32.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.75% | -32.90% | |||
| EBIT | -21.98% | -30.81% | |||
| EBITDA | -22.01% | -30.87% | |||
| EPS Basic | -7.09% | -30.37% | |||
| Normalized Basic EPS | -7.11% | -- | |||
| EPS Diluted | -7.09% | -30.37% | |||
| Normalized Diluted EPS | -7.11% | -- | |||
| Average Basic Shares Outstanding | 9.02% | 1.96% | |||
| Average Diluted Shares Outstanding | 9.02% | 1.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||